Pharmacists: On the Front Lines of Biosimilar Education

Tuesday October 16, 2018

Pharmacists are among the most trusted health care professionals in America. Millions of patients rely on their pharmacist for guidance on how best to take their prescription and over-the-counter medications. Every day, in the hospital, retail and community pharmacy settings, pharmacists counsel patients, dispense medicines and collaborate with doctors and health plans. So it is essential that they themselves are educated and current on the latest developments in disease treatment, including the use of biosimilars.

The Biosimilars Council has prioritized educational collaboration with pharmacists. Equipping pharmacists with accurate information about biosimilars assures that information reaches those patients who will benefit most from access to more-affordable versions of expensive biologic medicines to improve their care and quality of life.

In recognition of October as National Pharmacists Month, we’d like to celebrate these partnerships. Together with the American Pharmacists Association (APhA) we have jointly developed “Biosimilar Basics for Patients,” a new resource that introduces pharmacists and patients to biosimilars and answers questions they may have related to their safety and efficacy. APhA has additional resources on biosimilars for pharmacists and patients alike, including an online quiz that helps test one’s foundational understanding of biosimilars.

We are also proud to work and partner with the Academy of Managed Care Pharmacy(AMCP), American Society of Health-System Pharmacists (ASHP) and American Association of Colleges of Pharmacy (AACP) on a variety of education and policy issues.

Pharmacists are on the front lines when it comes to biosimilars education and we value our continued work with them.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.